Abstract:Infection by the intracellular bacterial pathogen Mycobacterium tuberculosis (Mtb) is a major cause of morbidity and mortality worldwide. Slow progress has been made in lessening the impact of tuberculosis (TB) on human health, especially in parts of the world where Mtb is endemic. Due to the complexity of TB disease, there is still an urgent need to improve diagnosis, prevention, and treatment strategies to control global spread of disease. Active research targeting avenues to prevent infection or transmission through vaccination, to diagnose asymptomatic carriers of Mtb, and to improve antimicrobial drug treatment responses is ongoing. However, this research is hampered by a relatively poor understanding of the pathogenesis of early infection and the factors that contribute to host susceptibility, protection, and the development of active disease. There is increasing interest in the development of adjunctive therapy that will aid the host in responding to Mtb infection appropriately thereby improving the effectiveness of current and future drug treatments. In this review, we summarize what is known about the host response to Mtb infection in humans and animal models and highlight potential therapeutic targets involved in TB granuloma formation and resolution. Strategies designed to shift the balance of TB granuloma formation toward protective rather than destructive processes are discussed based on our current knowledge. These therapeutic strategies are based on the assumption that granuloma formation, although thought to prevent the spread of the tubercle bacillus within and between individuals contributes to manifestations of active TB disease in human patients when left unchecked. This effect of granuloma formation favors the spread of infection and impairs antimicrobial drug treatment. By gaining a better understanding of the mechanisms by which Mtb infection contributes to irreversible tissue damage, down regulates protective immune responses, and delays tissue healing, new treatment strategies can be rationally designed. Granuloma-targeted therapy is advantageous because it allows for the repurpose of existing drugs used to treat other communicable and non-communicable diseases as adjunctive therapies combined with existing and future anti-TB drugs. Thus, the development of adjunctive, granuloma-targeted therapy, like other host-directed therapies, may benefit from the availability of approved drugs to aid in treatment and prevention of TB. In this review, we have attempted to summarize the results of published studies in the context of new innovative approaches to host-directed therapy that need to be more thoroughly explored in pre-clinical animal studies and in human clinical trials.

Natural products in anti-tuberculosis host-directed therapy

The past, present and future of tuberculosis treatment.

Anti-mycobacterial natural products and mechanisms of action

Exploring Anti-Tb Leads from Natural Products Library Originated from Marine Microbes and Medicinal Plants

Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity

Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Marine natural products as potential anti-tubercular agents

The War against Tuberculosis: A Review of Natural Compounds and Their Derivatives

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy

[Development of New Anti-Tuberculosis Drugs: the Strategy of Unconventional Microbial Culture and Silencing Gene Activation].

The potential of marine natural Products: Recent Advances in the discovery of Anti-Tuberculosis agents

New Anti-Tuberculosis Drugs: Strategies, Sources and New Molecules

Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections.

Host-directed therapy against tuberculosis: Concept and recent developments

Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review

The Antitubercular Activities of Natural Products with Fused-Nitrogen-Containing Heterocycles

Fluorescence-based Visual Analysis and Inhibitor Screening of Arylamine N-acetyltransferase 2, a Key Enzyme for Tuberculosis

Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis